Major adverse events during the first 30 days after coronary intervention according to GP Ia C807T genotype
| . | Genotype . | P . | ||
|---|---|---|---|---|
| CC (%) . | CT (%) . | TT (%) . | ||
| All (n = 652) | ||||
| No complications | 214 (93.0) | 305 (94.1) | 91 (92.9) | .84 |
| Composite endpoint | 16 (7.0) | 19 (5.9) | 7 (7.1) | |
| PTCA (n = 272) | ||||
| No complications | 92 (93.9) | 125 (94.7) | 41 (97.6) | .65 |
| Composite endpoint | 6 (6.1) | 7 (5.3) | 1 (2.4) | |
| DCA (n = 104) | ||||
| No complications | 34 (97.1) | 49 (94.2) | 15 (88.2) | .43 |
| Composite endpoint | 1 (2.9) | 3 (5.8%) | 2 (11.8) | |
| Stent (n = 276) | ||||
| No complications | 88 (90.7) | 131 (93.6) | 35 (89.7) | .62 |
| Composite endpoint | 9 (9.3) | 9 (6.4) | 4 (10.3) | |
| . | Genotype . | P . | ||
|---|---|---|---|---|
| CC (%) . | CT (%) . | TT (%) . | ||
| All (n = 652) | ||||
| No complications | 214 (93.0) | 305 (94.1) | 91 (92.9) | .84 |
| Composite endpoint | 16 (7.0) | 19 (5.9) | 7 (7.1) | |
| PTCA (n = 272) | ||||
| No complications | 92 (93.9) | 125 (94.7) | 41 (97.6) | .65 |
| Composite endpoint | 6 (6.1) | 7 (5.3) | 1 (2.4) | |
| DCA (n = 104) | ||||
| No complications | 34 (97.1) | 49 (94.2) | 15 (88.2) | .43 |
| Composite endpoint | 1 (2.9) | 3 (5.8%) | 2 (11.8) | |
| Stent (n = 276) | ||||
| No complications | 88 (90.7) | 131 (93.6) | 35 (89.7) | .62 |
| Composite endpoint | 9 (9.3) | 9 (6.4) | 4 (10.3) | |